

Literatur zur GfBK-Broschüre „Brustkrebs ganzheitlich und individuell behandeln“

Alabaster O, Vonderhaar BK, Shafie SM. Metabolic Modification by Insulin Enhances Methotrexate Cytotoxicity in MCF-7 Human Breast Cancer Cells. *Eur J Cancer Clin Oncol* 1981; 17: 1223-1228.

Andersen BL, Yang H, Farrar WB, Golden-Kreutz DM et al: Psychologic intervention improves survival for breast cancer patients, a randomized clinical trial. *Cancer* 2008; 113(12): 3450–3458.

Autier P, Boniol M, Gavin A, Vatten LJ: Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. *BMJ* 2011; 343 doi: 10.1136/bmj.d4411.

Autier P, Boniol M, LaVecchia C, Vatten L, Gavin A, Héry C, Heanue M: Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. *BMJ* 2010; 341: c3620.

Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ: Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. *Clin Pharmacol Ther* 2011; 90(4): 605-11.

Berry DA, Cirincione C, Henderson IC: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. *JAMA* 2006; 295(14): 1658-1667.

Coleman R, Bundred N, De Boer R, Llombarto A et al: Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST and E-ZO-FAST. *Cancer Res* 2009; 69 (24 Supplement): 4082.

Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic efficacy: A systematic review of the evidence from randomized controlled trials. *Cancer Treatment Reviews* 2007; 33: 407-418.

Bodinet C, Freudenstein J: Influence of cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. *Breast Cancer Res Treat* 2002; 76(1): 1-10.

Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari RK: The ratio of 16 α /2-Hydroxyestrone as a biologic marker of breast cancer risk. *Environ-Health-Persp* 1995; 103: 147-50.

Brufsky AM, Bosserman LD, Caradonna R, Haley B et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. *Clin Breast Cancer* 2009; 9 (2): 77-85.

Buck K, Vrieling A, Zaineddin AK, Becker S: Serum enterolactone and prognosis of postmenopausal breast cancer. *Journal of Clinical Oncology* 2011; 29 (28): 3730-3738.

Caan BJ, Natarajan L, Parker B, Gold EB et al: Soy food consumption and breast cancer prognosis. *Cancer Epidemiol Biomarkers Prev* 2011; 20(5): 854-8.

Cade JE, Burley VJ and Greenwood DC for the UK Women's Cohort Study Steering Group: Dietary fibre and risk of breast cancer in the UK Women's Cohort Study. *Int J Epidemiol* 2007; 36 (2): 431-438.

Caffrey P, Frenkel GD: Selenite Cytotoxicity in drug resistant and nonresistant human ovarian tumor Cells. *Cancer Res* 1992; 52: 4812.

Cardwell C, Abnet C, Cantwell M, Murray L: Exposure to oral bisphosphonates and risk of esophageal cancer. *JAMA* 2010; 304(6): 657-663.

Chen Q, Espey MG, Krishna MC, Mitchell JB et al: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. *PNAS* 2005; 102 (38): 13604-13609.

Clarke M, Collins R, Darby S, Davies C et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005; 366 (9503): 2087-106.

Cohen L, Chandwani K, Raghuram NV et al.: Effect of yoga on QOL, cortisol rhythm, and HRV for women with breast cancer undergoing radiotherapy. *Journal of Clinical Oncology* 2011; 29 (suppl, abstr 9009).

Cold S, Düring M, Ewertz M, Knoop A, Møller S: Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). *Br J Cancer* 2005; 93(6): 627-32.

Cramer JM, Teran-Garcia M, Jeffery EH: Enhancing sulforaphane absorption and excretion in healthy men through the combined consumption of fresh broccoli sprouts and a glucoraphanin-rich powder. *Br J Nutr* 2011; Sep 13:1-6. [Epub ahead of print]

Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A: Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. *BMJ* 2003; 326: 256-7.

De Amicis F, Thirugnansampanthan J, Cui Y et al: Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. *Breast Cancer Res Treat* 2010; 121(1): 1-11.

Denkert C, Loibl S, Noske A, Roller M et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *Journal of Clinical Oncology* 2009; 28(1): 105-113.

Dittmar T, Niggemann B, Zänker KS: Chronische Entzündungen - Rolle am Tumorgeschehen. *DZO* 2009; 41(4): 163-171.

Dorgan JF, Stanczyk FZ, Kahle LL, Brinton LA: Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. *Breast Cancer Res* 2010; 12(6): R98.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *The Lancet* 2012; 378 (9793): 771-784.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *The Lancet* 2005; 365: 1687-1717.

Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R: Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. *The Lancet* 2011; 378: 1461-1484.

Frenkel M, Mishra BM, Sen S, Yang P et al: Cytotoxic effects of ultra-diluted remedies on breast cancer cells. *Int Journal of Oncology* 2010;36 (2): 395-403.

Garland CF, Gorham ED, Mohr SB, Garland FC: Vitamin D for Cancer Prevention: Global Perspective. *Ann Epidemiol* 2009; 19: 468-483.

Gigerenzer G, Mata J, Frank R: Public Knowledge of Benefits of Breast and Prostate Cancer Screening in Europe. *J Natl Cancer Inst* 2009; 101 (17): 1216-1220.

Giltne JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL: Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. *J Clin Oncol* 2007; 25(21): 3007-14.

Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW et al: Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. *JAMA* 2011; 306(4): 385-393.

Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA* 2011; 305(6): 569-75.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. *N Engl J Med* 2009; 360 (7): 679-91.

Goodwin PJ, Ennis M, Pritchard K, Koo J and Hood N: Prognostic effects of 25-Hydroxyvitamin D levels in early breast cancer. *JCO* 2009; 23: 3757-3763.

Gröber U: Antioxidanzien und andere Mikronährstoffe in der komplementären Onkologie. *DZO* 2009; 41(4): 172-176.

Gröber U: Antioxidants and other micronutrients in complementary oncology. *Breast Care* 2009; 4: 13–20.

Gröber U: Supportiver Einsatz mitotroper Mikronährstoffe: Mitochondriale Toxizität von Zytostatika. *OM* 2011; 1: 10-14.

Grubbs CJ, Steele VE, Casebolt T, Juliana MM et al: Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. *Anticancer Res* 1995; 15(3): 709-16.

Guha N, Kwan ML, Quesenberry CP, Weltzien EK, Adrienne L. Castillo ALund Bette J. Caan BJ: Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. *Breast Cancer Research* 2009; 118 (2): 395-405.

Hansen NM, Ye X, Grube BJ, Giuliano A: Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. *Arch Surg* 2004; 139: 634-640.

Harbeck N, Schmitt M, Meisner C et al: Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer. *J Clin Oncol* 2009; 27: 15s (suppl; abstr 511).

Hayes DF, Thor AD, Dressler LG, Weaver D, et al; Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. *New Engl J Med* 2007; 357(15): 1496-506.

Holmes MD, Chen W, Feskanich D, Kroenke C, Colditz G: Physical activity and survival after breast cancer diagnosis. *JAMA* 2005; 293(20): 2479-2486.

Ionescu JG, Novotny J, Stejskal V, Lätsch A, Blaurock-Busch E, Eisenmann-Klein M: Hohe Akkumulation von Übergangsmetallen im Brustkrebsgewebe. *Umwelt-medizin-gesellschaft* 19(4): 269-273.

Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. *J Clin Oncol* 2011; 29(24): 3232-9.

Irwin ML, Smith AW, McTiernan A, Ballard-Barbash R, Cronin K, Gilliland FD, Baumgartner RN, Baumgartner KB, Bernstein L: Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. *J Clin Oncol* 2008; 26(24): 3958-64.

Jacob LM: Krebsstammzellen und ihre Nische als Lebensquelle des Todes. *DZO* 2011; 43(3): 112-118.

Jørgensen KJ, Zahl P-H, Gøtzsche PC: Breast cancer mortality in organised mammography screening in Denmark: comparative study. *BMJ* 2010; 340: c1241.

Joffroy CM, Buck MB, Stope MB, Popp SL, Pfizenmaier K, Knabbe C: Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. *Cancer Res* 2010; 70(4): 1314-1322.

Kalager M, Zelen M, Langmark F, Adami H-O: Effect of screening mammography on breast-cancer mortality in Norway. *N Engl J Med* 2010; 363: 1203-1210.

Kalager M, Adami H-O, Bretthauer M, Tamimi R: Overdiagnosis of Invasive Breast Cancer Due to Mammography Screening: Results From the Norwegian Screening Program. *Annals of Internal Medicine* 2012; 156(7): 491-499.

Keisch M, Vicini F, Beitsch P, Quiet C et al: American Society of Breast Surgeons MammoSite Radiation Therapy System Registry Trial: ductal carcinoma-in-situ subset analysis--4-year data in 194 treated lesions. *Am J Surg* 2009; 198(4): 505-7.

Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. *Brit Med J* 2010; 340: c693.

Kiyotani K, Mushiroda T, Hosono N, Tsunoda T: Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. *Pharmacogenet Genomics* 2010; 20(9): 565-8.

Lattrich Claus: Therapie von Mammakarzinomen. *Tumordiagn u Ther* 2010; 31: 324-27.

Lebeau A: Zielgerichtete Therapie des Mammakarzinoms – Rolle der Pathologie. *Gynäkologe* 2009; 42 (3): 194-200.

Levi F, Te VC, Randimbison L, La Vecchia C: Cancer risk in women with previous breast cancer. *Ann Oncol* 2003; 14(1): 71-73.

Li C, Daling J, Porter P et al: Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. *Cancer Res* 2009; 69: 6865.

Möbus V / In: Kreienberg R et al: Management des Mammakarzinoms. Springer 2006; 277-296.

Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S et al: Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. *Clin Pharmacol Ther* 2011; 89(5): 708-17.

Park-Wyllie LY, Mamdani M, Juurlink DN, Hawker GA et al: Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. *JAMA* 2011; 305(8): 783-789.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005; 353: 1659-1672.

Press MF, Sauter G, Buyse M et al: Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. *J Clin Oncol* 2011; 29(7): 859-67.

Sagar, SM: Antioxidants during anticancer therapy. *Focus on Alternative and Complementary Therapies* 2004; 9: 96-106.

Schernhammer ES, Kroenke CH, Laden F, Hankinson SE: Night Work and Risk of Breast Cancer. *Epidemiology* 2006; 17(1): 108-111.

Schlesinger-Raab A, Eckel R, Engel J, Sauer H, Löhrs U, Molls M, Hölzel D: Metastasiertes Mammakarzinom: Keine Lebensverlängerung seit 20 Jahren. Dtsch Arztebl 2005; 102 (40): A-2706-2714.

Schliep KC, Schisterman EF, Mumford SL, Pollack AZ et al: Caffeinated beverage intake and reproductive hormones among premenopausal women in the BioCycle Study. Am J Clin Nutr 2012; 95(2): 488-497.

Schmitz KH, Ahmed RL, Troxel AB, Cheville A et al: Weight lifting for women at risk for breast cancer-related lymphedema. JAMA 2010; 304 (22): 2441-2548.

Schroth W, Goetz MP, Hamann U, Fasching PA: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302(13): 1429-1436.

Schulte-Übbing C: Mammovision® – ein komplementäres Mamma-Diagnostik-Verfahren. Zeitschrift Ärzte für Naturheilverfahren (zaenmagazin) 2010; 2: 13-19.

Schulte-Uebbing C: Die Rolle von Endokrinen Disruptoren und Inflammation. Umwelt-medizin-gesellschaft 2011; 24(1): 43-46.

Shu XO, Zheng Y, Cai H, Gu K et al: Soy food intake and breast cancer survival. JAMA 2009; 302(22): 2437-2443.

Siegmund-Schultze N, Zylka-Menhorn V, Leinmüller R, Meyer, R: Hormontherapie und Brustkrebs: Ein Blick auf aktuelle Datenlage. Dtsch Arztebl 2008; 105(6): 260-266.

Simonini P, Breilin A, Gupta N, Malekpour M et al: Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor α in breast cancer cells. Cancer Res 2010; 70: 9175.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.

Ströhle A, Zänker K, Hahn A: Ernährung in der Onkologie - die Bedeutung von Mikronährstoffen. DZO 2010; 42(4): 157-167.

Sun C, Yuan J, Koh W, Yu M: Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis 2006; 27 (7): 1310–1315.

Tulin C, Eve F, Wedad H et al: Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. Cancer 2009, 115(24): 5780-5787.

Veronesi, U, Luini A, Mariani L et al.: Effect of menstrual phase on surgical treatment of breast cancer. The Lancet 1994; 343: 1545-1547.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM et al: Update of the National Surgical Adjuvant Breast and Bowel Project Study of tamoxifen and raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res; 3(6): 696-706.

Walker EM, Rodriguez AI, Kohn B, Ball RM et al: Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: A randomized controlled trial. JCO 2010; 28(4): 634-640.

Wenderlein JM: Aromatasehemmer riskant für das Gehirn? Geburtsh Frauenheilk 2005; 65(2): 144-148.

Weiss RB, Woolf SH, Demakos E, Holland JF et al; Cancer and Leukemia Group B. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide,

methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. *J Clin Oncol* 2003; 21 (9): 1825-35.

Zablotska LB, Neugut AI: Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. *Cancer* 2003; 97: 1404–1411.

Zahl P-H, Mæhlen J, Welch HG: The natural history of invasive breast cancers detected by screening mammography. *Arch Intern Med* 2008; 168(21): 2311-2316.

Zemzoum I, Kates RE, Ross JS et al: Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. *J Clin Oncol* 2003; 21(6): 1022-8.